Brice Hoffmann

Brice Hoffmann

Auto-generated profile, based on publicly available information

Brice Hoffmann

Iktos SAS, 75017 Paris, France

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2008 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
LJLaurent Jacob
Laurent Jacob
BHBrice Hoffmann
Brice Hoffmann
VSVéronique Stoven
Véronique Stoven
JVJean-Philippe Vert
Jean-Philippe Vert
The G-protein coupled receptor (GPCR) superfamily is currently the largest class of therapeutic targets. In silico prediction of interactions between GPCRs and small molecules in the transmembrane ligand-binding site is therefore a crucial step in the drug discovery process, which remains a daunting task due to the difficulty to characterize the 3D structure of most GPCRs, and to the limited amount of known ligands for some members of the superfamily. Chemogenomics, which attempts to characterize interactions between all members of a target class and all small molecules simultaneously, has recently been proposed as an interesting alternative to traditional docking or ligand-based virtual screening strategies.

7 October 2014 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
JMJean-Paul Mornon
Jean-Paul Mornon
BHBrice Hoffmann
Brice Hoffmann
Slavica JonicSlavica Jonic
Slavica Jonic
PLPierre Lehn
Pierre Lehn
ICIsabelle Callebaut
Isabelle Callebaut

22 February 2010 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
BHBrice Hoffmann
Brice Hoffmann
MZMikhail Zaslavskiy
Mikhail Zaslavskiy
JVJean-Philippe Vert
Jean-Philippe Vert
VSVéronique Stoven
Véronique Stoven
Background: Predicting which molecules can bind to a given binding site of a protein with known 3D structure is important to decipher the protein function, and useful in drug design. A classical assumption in structural biology is that proteins with similar 3D structures have related molecular functions, and therefore may bind similar ligands. However, proteins that do not display any overall sequence or structure similarity may also bind similar ligands if they contain similar binding sites. Quantitatively assessing the similarity between binding sites may therefore be useful to propose new ligands for a given pocket, based on those known for similar pockets. Results: We propose a new method to quantify the similarity between binding pockets, and explore its relevance for ligand prediction. We represent each pocket by a cloud of atoms, and assess the similarity between two pockets by aligning their atoms in the 3D space and comparing the resulting configurations with a convolution kernel. Pocket alignment and comparison is possible even when the corresponding proteins share no sequence or overall structure similarities. In order to predict ligands for a given target pocket, we compare it to an ensemble of pockets with known ligands to identify the most similar pockets. We discuss two criteria to evaluate the performance of a binding pocket similarity measure in the context of ligand prediction, namely, area under ROC curve (AUC scores) and classification based scores. We show that the latter is better suited to evaluate the methods with respect to ligand prediction, and demonstrate the relevance of our new binding site similarity compared to existing similarity measures. Conclusions: This study demonstrates the relevance of the proposed method to identify ligands binding to known binding pockets. We also provide a new benchmark for future work in this field. The new method and the benchmark are available at http://cbio.ensmp.fr/paris/.

21 March 2011 in Chemical Senses
Verified
Journal Article
Open access
PDF file
MRMariam Raliou
Mariam Raliou
MGMarta Grauso
Marta Grauso
BHBrice Hoffmann
Brice Hoffmann
CSClaire Schlegel–Le-Poupon
Claire Schlegel–Le-Poupon
CNClaude Nespoulous
Claude Nespoulous
LBLoïc Briand
Loïc Briand
Umami is the typical taste induced by monosodium glutamate (MSG), which is thought to be detected by the heterodimeric G protein–coupled receptor, T1R1 and T1R3. Previously, we showed that MSG detection thresholds differ substantially between individuals and we further showed that nontaster and hypotaster subjects are associated with nonsynonymous single polymorphisms occurring in the T1R1 and T1R3 genes. Here, we show using functional expression that both amino acid substitutions (A110V and R507Q) in the N-terminal ligand-binding domain of T1R1 and the 2 other ones (F749S and R757C), located in the transmembrane domain of T1R3, severely impair in vitro T1R1/T1R3 response to MSG. A molecular model of the ligand-binding region of T1R1/T1R3 provides a mechanistic explanation supporting functional expression data. The data presented here support causal relations between the genotype and previous in vivo psychophysical studies in human evaluating sensitivity to MSG.

5 November 2016 in Hepatology
Verified
Journal Article
Open access
PDF file
jean-louis Delaunayjean-louis Delaunay
jean-louis Delaunay
BBBruneau Bruneau
Bruneau Bruneau
BHBrice Hoffmann
Brice Hoffmann
ADAnne‐Marie Durand‐Schneider
Anne‐Marie Durand‐Schneider
VBVéronique Barbu
Véronique Barbu
TSTounsia AIT SLIMANE
Tounsia AIT SLIMANE
ABCB4 (MDR3) is an adenosine triphosphate (ATP)‐binding cassette (ABC) transporter expressed at the canalicular membrane of hepatocytes, where it mediates phosphatidylcholine (PC) secretion. Variations in the ABCB4 gene are responsible for several biliary diseases, including progressive familial intrahepatic cholestasis type 3 (PFIC3), a rare disease that can be lethal in the absence of liver transplantation. In this study, we investigated the effect and potential rescue of ABCB4 missense variations that reside in the highly conserved motifs of ABC transporters, involved in ATP binding. Five disease‐causing variations in these motifs have been identified in ABCB4 (G535D, G536R, S1076C, S1176L, and G1178S), three of which are homologous to the gating mutations of cystic fibrosis transmembrane conductance regulator (CFTR or ABCC7; i.e., G551D, S1251N, and G1349D), that were previously shown to be function defective and corrected by ivacaftor (VX‐770; Kalydeco), a clinically approved CFTR potentiator. Three‐dimensional structural modeling predicted that all five ABCB4 variants would disrupt critical interactions in the binding of ATP and thereby impair ATP‐induced nucleotide‐binding domain dimerization and ABCB4 function. This prediction was confirmed by expression in cell models, which showed that the ABCB4 mutants were normally processed and targeted to the plasma membrane, whereas their PC secretion activity was dramatically decreased. As also hypothesized on the basis of molecular modeling, PC secretion activity of the mutants was rescued by the CFTR potentiator, ivacaftor (VX‐770). Conclusion: Disease‐causing variations in the ATP‐binding sites of ABCB4 cause defects in PC secretion, which can be rescued by ivacaftor. These results provide the first experimental evidence that ivacaftor is a potential therapy for selected patients who harbor mutations in the ATP‐binding sites of ABCB4. (Hepatology 2017;65:560‐570)

1 September 2015 in mBio
Verified
Journal Article
Open access
PDF file
TRThibaut Rosay
Thibaut Rosay
ABAlexis Bazire
Alexis Bazire
SDSuraya Diaz
Suraya Diaz
TCThomas Clamens
Thomas Clamens
ABAnne-Sophie Blier
Anne-Sophie Blier
OLOlivier Lesouhaitier
Olivier Lesouhaitier
Considerable evidence exists that bacteria detect eukaryotic communication molecules and modify their virulence accordingly. In previous studies, it has been demonstrated that the increasingly antibiotic-resistant pathogenPseudomonas aeruginosacan detect the human hormones brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) at micromolar concentrations. In response, the bacterium modifies its behavior to adapt to the host physiology, increasing its overall virulence. The possibility of identifying the bacterial sensor for these hormones and interfering with this sensing mechanism offers an exciting opportunity to directly affect the infection process. Here, we show that BNP and CNP strongly decreaseP. aeruginosabiofilm formation. Isatin, an antagonist of human natriuretic peptide receptors (NPR), prevents this effect. Furthermore, the human NPR-C receptor agonist cANF4-23mimics the effects of natriuretic peptides onP. aeruginosa, while sANP, the NPR-A receptor agonist, appears to be weakly active. We showin silicothat NPR-C, a preferential CNP receptor, and theP. aeruginosaprotein AmiC have similar three-dimensional (3D) structures and that both CNP and isatin bind to AmiC. We demonstrate that CNP acts as an AmiC agonist, enhancing the expression of theamioperon inP. aeruginosa. Binding of CNP and NPR-C agonists to AmiC was confirmed by microscale thermophoresis. Finally, using anamiCmutant strain, we demonstrated that AmiC is essential for CNP effects on biofilm formation. In conclusion, the AmiC bacterial sensor possesses structural and pharmacological profiles similar to those of the human NPR-C receptor and appears to be a bacterial receptor for human hormones that enablesP. aeruginosato modulate biofilm expression.IMPORTANCEThe bacteriumPseudomonas aeruginosais a highly dangerous opportunist pathogen for immunocompromised hosts, especially cystic fibrosis patients. The sites ofP. aeruginosainfection are varied, with predominance in the human lung, in which bacteria are in contact with host molecular messengers such as hormones. The C-type natriuretic peptide (CNP), a hormone produced by lung cells, has been described as a bacterial virulence enhancer. In this study, we showed that the CNP hormone counteractsP. aeruginosabiofilm formation and we identified the bacterial protein AmiC as the sensor involved in the CNP effects. We showed that AmiC could bind specifically CNP. These results show for the first time that a human hormone could be sensed by bacteria through a specific protein, which is an ortholog of the human receptor NPR-C. The bacterium would be able to modify its lifestyle by favoring virulence factor production while reducing biofilm formation.